Injecting ghrelin into a specific brain region (PVN) dose-dependently sped up intestinal transit in rats by activating a signaling chain from central ghrelin receptors through neuropeptide Y to gut nerve acetylcholine receptors.
3-step signaling chain identifiedGhrelin activates brain GHSR receptors → neuropeptide Y signaling → enteric cholinergic neurons to control gut motility
What the researchers found
Ghrelin injected into the paraventricular nucleus (PVN) at doses of 0.03, 0.08, and 0.24 nM dose-dependently accelerated small intestinal transit (SIT) in rats. This effect was systematically dissected:
- GHSR antagonist (D-Lys3-GHRP6, 1 nM) competitively inhibited ghrelin's excitatory effect on SIT and interdigestive myoelectric complex (IMC) activity
- NPY neutralization in the PVN using anti-NPY immunoglobulin also diminished the excitatory effect on IMC
- Peripheral muscarinic acetylcholine receptor blockade with intravenous atropine reduced ghrelin's gut motility effects
- c-Fos immunohistochemistry showed ghrelin upregulated neuronal activation in the PVN, other central nuclei, and enteric nervous plexuses of the stomach, duodenum, and proximal colon — all dependent on central GHSR activation
Why it matters
Millions of people suffer from gut motility disorders like gastroparesis, irritable bowel syndrome, and post-operative ileus. Understanding the precise brain-gut signaling pathway that ghrelin uses to control intestinal movement could lead to more targeted therapies. This study maps out a complete signaling chain — from a specific brain nucleus through neuropeptide intermediaries to gut nerve endings — providing multiple potential intervention points for drug development.
How the study worked
Thirty-six male Sprague-Dawley rats were surgically fitted with duodenal catheters and PVN cannulas. Multiple experimental groups received: ghrelin at three doses (0.03, 0.08, 0.24 nM) into the PVN; GHSR antagonist D-Lys3-GHRP6 alone or before ghrelin; anti-NPY IgG into the PVN; or intravenous atropine. Small intestinal transit was measured via the catheter system. Interdigestive myoelectric complex recordings were obtained through implanted intestinal electrodes. Neuronal activation was mapped using c-Fos immunohistochemistry in brain regions and enteric nervous system plexuses.
What this study cannot tell us
The study was conducted in anesthetized rats with surgically implanted cannulas and catheters, which is a highly artificial setting that may not reflect normal physiology. Direct PVN injection bypasses the normal routes by which ghrelin reaches the brain. Only male rats were used. The 36-rat sample was split across multiple experimental groups, resulting in small group sizes. The study examined acute effects only — chronic ghrelin exposure might produce different results due to receptor desensitization.
How to read the evidence
This is a preclinical mechanistic study in rats using invasive surgical techniques and pharmacological blockade experiments. The systematic approach of blocking each pathway component adds rigor. However, the findings are limited to an animal model under artificial conditions and have not been validated in humans.
When this study was published
Published in 2015, this study provides foundational mechanistic data on ghrelin's brain-gut signaling that remains relevant to ongoing development of ghrelin-based gut motility drugs.
The bigger picture
This study adds important mechanistic detail to the growing understanding of ghrelin as a master regulator of the brain-gut axis. Ghrelin agonists (like relamorelin) are already being developed for gastroparesis, while ghrelin receptor blockers are being explored for addiction and obesity. By mapping the complete signaling chain from brain to gut, this work helps explain why targeting ghrelin can have such wide-ranging effects on digestive function and informs the design of more precise gut-motility drugs.
Questions still open
- Does circulating ghrelin from the stomach reach the PVN in sufficient concentrations to produce the same gut motility effects seen with direct injection?
- Could targeting the NPY signaling step specifically allow for gut motility modulation without the appetite effects of ghrelin?
- Do ghrelin's effects on gut motility through this pathway contribute to the gastrointestinal side effects seen with GLP-1 agonists that suppress ghrelin?
Common questions
What is the paraventricular nucleus and why is it important for gut function?
Could this research lead to new treatments for digestive problems?
Read the original research
Extrinsic ghrelin in the paraventricular nucleus increases small intestinal motility in rats by activating central growth hormone secretagogue and enteric cholinergic receptors.
Peptides, 74, 43-9
Citation
Wang, Yan; Chen, Fenrong; Shi, Haitao; Jiang, Jiong; Li, Hong; Qin, Bin; Li, Yong. (2015). Extrinsic ghrelin in the paraventricular nucleus increases small intestinal motility in rats by activating central growth hormone secretagogue and enteric cholinergic receptors.. Peptides, 74, 43-9. https://doi.org/10.1016/j.peptides.2015.09.009